ONJ, medical cannabis and a nod to Australian cannabis stocks

By Jonathan Jackson. Published at Aug 5, 2019, in Features

This is an older exclusive article for FinFeed subscribers which is now opened up.  If you'd like to see new exclusive articles every week, please subscribe to our newsletter.

I don’t usually watch 60 Minutes. I find it overproduced and overhyped these days and pine for the time when Jana Wendt and George Negus, were going toe-to-toe with people.

I was just a kid back then, but those two alone, along with Ray Martin and Ian Leslie, were part of the reason I wanted to become a journalist or writer or any part of the media industry.

I wanted to wear a tweed jacket and throw it over my shoulder and go into war zones.

I don’t remember that initial 60 Minutes team putting themselves before the story, as seems to happen a lot these days on a variety of current affairs shows, but sometimes the current crop produce a story I am interested in and last night (Sunday, 4 August) it had to do with Olivia Newton John.

Here I go being nostalgic again. As a kid in the time of 60 Minutes’ glory years, I, along with many others, hoped Newton John could be hopelessly devoted to me. I was very much pre-teen in 1978 when Grease came out, so please forgive me.

Today, as a man in his mid-to-late 40s who writes a lot about medical cannabis and related listed companies, my interest is always piqued by medical cannabis based human interest stories.

So when Liz Hayes interviewed Sandy about cannabis use, I felt it was worth repeating Newton John’s fight with stage 4 cancer and how medical cannabis helped her get through it.

She tells Hayes that her husband John Easterling had grown cannabis for medical purposes for her.

"I really believe the cannabis has made a huge difference," says Olivia.

"I'm confident," John concurs.

All three in the family, including daughter Chloe are now converts.

Here’s a look at the full interview:

Of course, this is a high profile story.

There are many other inspirational stories out there, that don’t involve Australian icons.

Like Rebecca Sewell’s which you can read about here.

Or Kristen Courtney who was diagnosed at the age of sixteen with juvenile rheumatoid arthritis, which quickly developed into an autoimmune disorder leaving her bedridden for four years. Kristen founded Cannabis International with doctor William Courtney after cannabis reduced her pain.

One of the more famous cases is that of Charlotte Figi who had her first seizure at just three months old and by five couldn’t walk, eat or talk. Cannabis oil was her saviour and now there is a recognised cannabis strain named after her called Charlotte’s Web.

You can read all about Charlotte’s story here.

Of course, cannabis is no miracle cure. It obviously has its benefits, but there is little known about any side effects or long-term effects.

We know the psychoactive element has been taken out, but beyond that we have to put our faith in the researchers and their findings as to the full suite of medical benefits.

Companies such as the profitable Ecofibre (ASX:EOF), which is heading toward a billion dollar market cap, THC Global (ASX:THC), AusCann (ASX:AC8), Elixinol (ASX:EXL), Cann Group (ASX:CAN), Althea (ASX:AGH) and MGC Pharmaceuticals (ASX:MXC) are working hard in the space.

As Business News Australia reports, “Cannvalate CEO and co-founder Dr Sud Agarwal describes Australia as "the next Canada" with positive trends since medicinal cannabis was legalised in 2016, just two years after similar regulations took effect in the North American country.

"The growth trajectory of medicinal cannabis users that we've seen so far in Australia is very similar to what was seen in Canada in the early days of commercial legalisation," says Agarwal.

"Fortunately, more GPs and medical specialists are starting to learn more about the benefits of medicinal cannabis as well as how to prescribe it to patients.

"There has recently been a significant shift recently in how the medical profession views medicinal cannabis and its place in the health sector."

If that is true then the Australian medical cannabis industry is in good shape and stories such as Olivia Newton John’s may not be niche stories about the miracle of medical cannabis for too much longer. They would actually given widespread credence.


Where to invest $1,000 right now

When the experts at Next Investors have a stock pick, it may pay to listen.

The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.

They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.

Click the link below to see what they are currently investing in.


SEE THE PORTFOLIO

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Australian ASX Small Cap stocks | Why Finfeed.com is Australia’s leading small cap publication

Founded seven years ago, Finfeed.com is Australia’s leading and longest standing website for investor and finance news, education and expert opinion.

Published by StocksDigital, Finfeed was created to report daily on the comings and goings of ASX listed stocks in the small cap market.

As the first digital publication dedicated specifically to this space, Finfeed soon became the most trusted publication in the market, quickly garnering over two million page views – a number that continues to rise.

Finfeed.com provides its readers with informative articles that tackle the latest in market moving #ASX small cap news, plus exclusive content you won’t find anywhere else. It is aimed at those with an interest in investing, market education, company performance, start-ups and much more.

Finfeed.com is the only media organisation operating under the strength of a Financial Services License and is backed by leading journalists and analysts all with brands of their own.

The website aims to inform, educate and entertain with content that drills down into the heart of financial matters.

Finfeed is a leading source of investor and market information, with everything investors need to know about how to invest written in a way that anyone can understand. 

Over the years, the website has expanded beyond exclusively reporting on small caps, to profile Australia’s leading ASX listed small, mid and large caps as well as some of the country’s most successful CEOs and business leaders to find out what makes them tick.

Every day you will find fresh content covering:

Fast Facts

Over 4,000 articles published

Over 2.3 Million Page Views and counting

Over 10,000 followers on social media

Subscriber list growing by 2% monthly

Thanks for subscribing!

X